CORRECTION

Pathol. Oncol. Res., 24 February 2022

Volume 27 - 2021 | https://doi.org/10.3389/pore.2021.1610250

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors

  • Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China

In the original article, there were mistakes in the legend for all of the figures as published. The source of the pictures cited in the article were not included. The correct legends appear below.

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

FIGURE 5

FIGURE 6

FIGURE 7

FIGURE 8

The sources for the figures have been added to the reference list, and the reference numbering has been updated to accommodate this. The new references are appear below.

The authors apologize for this error and state that authorization has been obtained from the author of each picture, and this does not change the scientific conclusions of the article in any way. The original article has been updated.

References

  • 3.

    PriorIALewisPDand MattosC.A Comprehensive Survey of Ras Mutations in Cancer. Cancer Res (2012) 72(10):245767. 10.1158/0008-5472.can-11-2612

  • 4.

    SimanshuDKNissleyDVand MccormickF.RAS Proteins and Their Regulators in Human Disease. Cell (2017) 170(1):17.

  • 14.

    HuiliLFeiJJiweiRTaoLYadongC.Research Advances on KRAS and Its Inhibitors. Acta Pharmaceutica Sinica (2020) 44(1):4355.

  • 20.

    XinLYijunWand PingyuL. Recent Advancement In Targeting The KRASG12C Mutant For Cancer Therapy. Acta Pharmaceutica Sinica (2021) 56(2):37482.

  • 30.

    FellJBFischerJPBaerBRBlakeJFBouhanaKBriereDMet alIdentification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. J Med Chem (2020) 63(13):667993. 10.1021/acs.jmedchem.9b02052

  • 33.

    TranTHAlexanderPDharmaiahSAgamasuCand BaliusTE. The Small Molecule BI-2852 Induces A Nonfunctional Dimer Of KRASProc National Academy Sci. (2020) 117(7).

Summary

Keywords

KRAS mutation, targeted drugs, oncogene, inhibitor, oncology

Citation

Yang A, Li M and Fang M (2022) Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors. Pathol. Oncol. Res. 27:1610250. doi: 10.3389/pore.2021.1610250

Received

09 December 2021

Accepted

29 December 2021

Published

24 February 2022

Volume

27 - 2021

Edited and reviewed by

József Timar, Semmelweis University, Hungary

Updates

Copyright

*Correspondence: Min Li,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article